

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8-75	Sparsentan	≥ 30
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30
ACTHAR FOR TREATMENT OF POST-TRANSPLANT FSGS (COMING SOON) (Mallinckrodt)	Recurrent FSGS	18+	Acthar	UPCR > 1 gram/day
STUDY OF VX-147 IN ADULTS WITH APOL1-MEDIATED FSGS (Vertex)	APOL1-Mediated FSGS	18-65	VX-147	≥ 30
THE TRACTION-2 STUDY (Goldfinch Bio)	FSGS, treatment-resistant MCD, Diabetic Nephropathy	18-75	GFB-887	≥ 45
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	FSGS, IgAN, MN	18+	BI 685509	≥ 20 & < 90
AFFINITY (Chinook)	FSGS, IgAN, Alport Syndrome, DKD, Diabetic Nephropathy	18+	Atrasentan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0-75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
ACTION (AUSTRALIA - ACTIVE, NOT RECRUITING) (Dimerix)	FSGS	18-80	Propagermanium	≥ 25
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



This is a living document and was last updated on 4/6/21.

See next page for more IgAN, C3G, C3GN, and IC-MPGN Trials.

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PROTECT (Travere)	IgAN	18+	Sparsentan	≥ 30
SPARTAN (LEICESTER) (Travere)	IgAN	18+	Sparsentan	≥ 30
ALIGN (Chinook)	IgAN	18+	Atrasentan	≥ 30
SAFETY & TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS & ADULTS WITH IGAN (CALIFORNIA, EL PASO TEXAS, LONDON) (Chinook)	IgAN	18+	BION-1301	> 45
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
THE ARTEMIS-IGAN STUDY (Omeros)	IgAN	18+	OMS721	≥ 30
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (Alnylam)	IgAN	18–65	Cemdisiran	≥ 30
NEFIGARD (Calliditas)	IgAN	18+	Nefecon	≥ 45
STUDY OF RAVULIZUMAB IN IGAN & PROLIFERATIVE LUPUS NEPHRITIS (Alexion)	IgAN, Lupus Nephritis	18-75	Ravulizumab	≥ 30
SAFETY & EFFICACY OF LNP023 IN ADULTS WITH KIDNEY DISEASE CAUSED BY INFLAMMATION (ACTIVE, NOT RECRUITING) (Novartis)	IgAN	18+	LNP023	≥ 30
SAFETY & EFFICACY OF VIS649 FOR IGAN (Visterra)	IgAN	18+	VIS649	≥ 45
EFFECTIVENESS & SAFETY OF IONIS-FB-LRX IN IGAN (AUSTRALIA, CANADA, NEW ZEALAND) (Ionis)	IgAN	18–75	IONIS-FB-LRx	> 40
THE NOBLE STUDY (Apellis)	C3G or IC-MPGN that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 30
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≤ 75

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/6/21.



See next page for more C3G and MN Trials.

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
EFFICACY & SAFETY OF LNP023 IN C3G PATIENTS TRANSPLANTED & NOT TRANSPLANTED (Novartis)	C3G	18-65	LNP023	≥ 30
M-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
NEW-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
REBOOT (GlaxoSmithKline)	MN	18-75	Belimumab, Rituximab	≥ 40
EFFICACY & SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023	≥ 45
EFFICACY & SAFETY OF OBINUTUZUMAB IN PARTICIPANTS WITH PRIMARY MN (COMING SOON) (Hoffmann-La Roche)	MN	18-75	Obinutuzumab	≥ 40

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/6/21.



NEPHCURE[®]
Kidney International